Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
+0.03 (1.44%)
Real-time:   1:03PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.07 - 2.14
52 week 1.84 - 5.30
Open 2.07
Vol / Avg. 797,904.00/2.51M
Mkt cap 339.00M
P/E 576.09
Div/yield     -
EPS 0.00
Shares 159.14M
Beta 2.65
Inst. own 38%
Nov 3, 2016
Q3 2016 Geron Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Geron Corp Update on the Imetelstat Phase 2 Trial in Myelofibrosis and Phase 2/3 Trial in Myelodysplastic Syndromes Call - Webcast
Aug 3, 2016
Q2 2016 Geron Corp Earnings Call
Aug 3, 2016
Q2 2016 Geron Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -4093.36% 0.13%
Operating margin -4223.22% -1.54%
EBITD margin - 2.21%
Return on average assets -24.70% 0.03%
Return on average equity -25.97% 0.03%
Employees 17 -
CDP Score - -


149 Commonwealth Dr Ste 2070
MENLO PARK, CA 94025-1133
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.

Officers and directors

Hoyoung Huh Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Daniel Mark Bradbury Independent Director
Age: 54
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters